Oligomerix, Inc.
PrivateLast Round
Grant
Nov 18, 2023
Total Funding Raised
$14.64M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Oligomerix, Inc. is a clinical-stage biotechnology company that develops oral, small molecule therapeutics for neurodegenerative diseases such as Alzheimer's by targeting the aggregation of the tau protein.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oligomerix, Inc. Comparables
Compare Oligomerix, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Treventis Corporation | 86% | |
| Asceneuron | 84% | |
| Alzprotect | 81% |
Oligomerix, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 18, 2023 | ||||
| Grant | Aug 9, 2022 | ||||
| Series B Extension | Jun 2, 2022 | ||||
| Grant | Sep 15, 2020 | ||||
| Series B | May 22, 2013 | ||||
Series A | Apr 23, 2012 |
Oligomerix, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Wheatley Partners | Series A |
| NIH RADx | Grant |
| National Institute on Aging | Grant |
| Alzheimer's Drug Discovery Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 63% MoM, reaching 1.5K.
- Jan 26, 2026
Monthly visitors grew 286% MoM, from 235 to 906.
Recent news
Latest coverage and updates
- hiresAug 31, 2026
Oligomerix hired Cara Cassino as interim president and chief executive officer on Aug 31st '26.
Oligomerix, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Oligomerix, Inc.'s valuation, stock price, and market status.
Is Oligomerix, Inc. a public or private company?
Oligomerix, Inc. is a private company.
What is the current stock price of Oligomerix, Inc.?
Oligomerix, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is Oligomerix, Inc. worth (valuation)?
Valuation information for Oligomerix, Inc. is not publicly available.
Can I buy Oligomerix, Inc. stock?
Oligomerix, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Oligomerix, Inc.'s last funding round?
Oligomerix, Inc.'s most recent funding round was Grant on November 18, 2023.
Who are the main investors in Oligomerix, Inc.?
Key investors in Oligomerix, Inc. include Wheatley Partners.
Will Oligomerix, Inc. IPO soon?
No public IPO plans have been announced for Oligomerix, Inc..
How can I track Oligomerix, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Oligomerix, Inc.'s secondary market activity and sign up for updates.